Glucagon News and Research

RSS

Exploring 'food noise': Study sheds light on eating thoughts and obesity treatment breakthroughs

Study delves into the concept of 'food noise,' referring to persistent thoughts about eating, and assesses its impact on eating behaviors and obesity treatments. It explores how GLP-1RAs, a class of drugs used for weight management, might influence food cue reactivity, potentially offering new insights into obesity treatment and the psychological aspects of eating behaviors.

30 Nov 2023

The role of the brainstem in appetite suppression

The role of the brainstem in appetite suppression.

28 Nov 2023

Single injection of novel hydrogel could replace weekly diabetes injections

Materials engineers at Stanford University have developed a novel hydrogel drug delivery system that transforms daily or weekly injections of diabetes and weight control drugs like Ozempic, Mounjaro, Trulicity, Victoza, and others to just once every four months.

22 Nov 2023

New study links DNA methylation in GLP1R gene to obesity without metabolic disorders

The study investigates the role of epigenetic changes in GLP1R gene polymorphisms on metabolically healthy obesity (MHO), revealing that apart from genetic variations, DNA methylation significantly influences the occurrence of MHO.

20 Nov 2023

Nutrition and aging: A two-way relationship

With so much hype in the media about miracle diets and nutritional supplements, one is invariably tempted to look for a single, food-based magic bullet that will increase the likelihood of living a longer, healthier life.

3 Nov 2023

Study highlights safety concerns of SGLT2i in patients with diabetes and cancer

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have heart- and kidney-related benefits for patients with and without diabetes that go beyond their initial indication for lowering blood sugar levels.

2 Nov 2023

Citrus compounds show zesty promise in type 2 diabetes management

Citrus compounds show promise in type 2 diabetes management, reducing blood glucose and mitigating metabolic complications without a clear threshold in humans for bioflavonoid efficacy.

2 Nov 2023

How does the Mediterranean diet impact insulin resistance and sensitivity in obese individuals?

Researchers evaluate the associations between adherence to the Mediterranean diet, insulin secretion, resistance, and sensitivity in obese individuals.

30 Oct 2023

Novel GLP-1 receptor agonists offer hope for long-lasting diabetes treatment

In a study published in Scientific Reports, researchers engineer long-lasting GLP-1 receptor agonists by fusing GLP-1 with an HSA-binding protein. These chimeric molecules show promise for the treatment of type 2 diabetes due to their stability, functionality, and high affinity for the GLP-1 receptor and human serum albumin.

22 Oct 2023

Exploring the impact of solid oat polar lipid-enriched breakfasts on metabolic health

Researchers investigate if oat polar lipid compounds improve glucose tolerance, gut hormonal responses, and triglyceridemia.

20 Oct 2023

Oral diabetes and obesity meds danuglipron and orforglipron show promise but have gastrointestinal drawbacks

New orally-administered GLP-1 receptor agonists danuglipron and orforglipron show promise in treating type 2 diabetes and obesity, according to a systematic review. While effective in glycemic control and weight reduction, these drugs come with gastrointestinal side effects that may lead to treatment discontinuation.

17 Oct 2023

Skyrocketing demand for weight-loss drugs prompts calls for informed prescribing

The study reveals a significant increase in the usage of GLP-1 receptor agonists, particularly Ozempic and Trulicity, for weight management and Type 2 diabetes in the U.S. from 2014 to 2022. Amidst rapid growth and shortages, the paper calls for evidence-based decision-making to ensure stable medication supply and effective treatment.

17 Oct 2023

Tirzepatide boosts weight loss in lifestyle intervention patients, but comes with a catch

In a groundbreaking 84-week-long study, researchers found that tirzepatide, a medication initially designed for treating type 2 diabetes, significantly bolstered weight loss in overweight and obese patients already on intensive lifestyle programs. While the drug showed promise in further reducing body weight and improving cardiometabolic factors, mild to moderate gastrointestinal side effects were the most common drawback.

16 Oct 2023

Diet drinks may affect blood sugar levels, insulin resistance and gut microbiome

‘Full fat’ sugary drinks such as colas increase the risk of obesity and are generally off-limits for diabetics.

14 Oct 2023

Presidential advisory by the American Heart Association: connecting cardiovascular, kidney, and metabolic health

The interplay among chronic kidney disease, metabolic risk factors, and the cardiovascular system.

11 Oct 2023

Black Chokeberry (Aronia melanocarpa) diabetes benefits: Hope or hype?

Researchers compared the effects of fermented and non-fermented Aronia melanocarpa berries on glycemic markers in Type 2 Diabetes Mellitus patients. Despite the berries' high antioxidant potential and past studies suggesting benefits, this rigorous trial found no significant impact on waist circumference, insulin sensitivity, or glucose levels.

10 Oct 2023

Health experts redefine cardiovascular disease risk, prevention and management

Health experts are redefining cardiovascular disease (CVD) risk, prevention and management, according to a new American Heart Association presidential advisory published today in the Association's flagship journal Circulation.

9 Oct 2023

How is TikTok's #Ozempic trend impacting diabetes patients?

A recent study analyzed TikTok videos with the hashtag "Ozempic," highlighting the platform's influence on promoting the weight loss drug. The surge in popularity resulted in medication shortages for diabetes patients, emphasizing the need for careful monitoring and collaboration among health professionals and social media platforms.

5 Oct 2023

GLP-1 weight loss drugs linked to heightened GI risks, says new study

Study from JAMA reveals that users of GLP-1 agonists, recent drugs for weight management, show a heightened risk of gastrointestinal complications like intestinal obstruction, gastroparesis, and pancreatitis. Though these effects are rare, those considering these drugs for weight loss should weigh the benefits against potential risks, especially if not using them for diabetes.

5 Oct 2023

GLP-1 agonists linked to higher risk for gastrointestinal complications

They're being hailed as an effective way to lose weight, but diabetes drugs like Ozempic may come with a heightened risk of severe gastrointestinal problems.

5 Oct 2023

Glucagon News and Research

Exploring 'food noise': Study sheds light on eating thoughts and obesity treatment breakthroughs

The role of the brainstem in appetite suppression

Single injection of novel hydrogel could replace weekly diabetes injections

New study links DNA methylation in GLP1R gene to obesity without metabolic disorders

Nutrition and aging: A two-way relationship

Study highlights safety concerns of SGLT2i in patients with diabetes and cancer

Citrus compounds show zesty promise in type 2 diabetes management

How does the Mediterranean diet impact insulin resistance and sensitivity in obese individuals?

Novel GLP-1 receptor agonists offer hope for long-lasting diabetes treatment

Exploring the impact of solid oat polar lipid-enriched breakfasts on metabolic health

Oral diabetes and obesity meds danuglipron and orforglipron show promise but have gastrointestinal drawbacks

Skyrocketing demand for weight-loss drugs prompts calls for informed prescribing

Tirzepatide boosts weight loss in lifestyle intervention patients, but comes with a catch

Diet drinks may affect blood sugar levels, insulin resistance and gut microbiome

Presidential advisory by the American Heart Association: connecting cardiovascular, kidney, and metabolic health

Black Chokeberry (Aronia melanocarpa) diabetes benefits: Hope or hype?

Health experts redefine cardiovascular disease risk, prevention and management

How is TikTok's #Ozempic trend impacting diabetes patients?

GLP-1 weight loss drugs linked to heightened GI risks, says new study

GLP-1 agonists linked to higher risk for gastrointestinal complications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News